Trending Topic

3d illustration of human body liver
12 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Allan A Lima Pereira, Gabriel Lenz, Tiago Biachi de Castria

Despite being considered a rare type of malignancy, constituting only 3% of all gastrointestinal cancers, the incidence of biliary tract cancers (BTCs) has been increasing worldwide in recent years, with about 20,000 new cases annually only in the USA.1–3 These cancers arise from the biliary epithelium of the small ducts in the periphery of the liver […]

Barbara Eichhorst, EHA 2022: What did the GAIA/CLL13 study teach us about the impact of venetoclax and obinutuzumab in fit patients with CLL?

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jul 18th 2022

Prof Barbara Eichhorst (University Hospital Cologne, Cologne, Germany) discusses the impact of venetoclax plus obinutuzumab on the treatment of patients with chronic lymphocytic leukaemia (CLL) who are unfit for chemoimmunotherapy.

The abstract ‘TIME-LIMITED VENETOCLAX-OBINUTUZUMAB +/- IBRUTINIB IS SUPERIOR TO CHEMOIMMUNOTHERAPY IN FRONTLINE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PFS CO-PRIMARY ENDPOINT OF THE RANDOMIZED PHASE 3 GAIA/CLL13 TRIAL’ (Abstract: LB2365) was presented at the EHA2022 Congress, 9-12 June 2022.

Questions

  1. What has been the impact of venetoclax plus obinutuzumab on the treatment of patients with chronic lymphocytic leukaemia (CLL) who are unfit for chemoimmunotherapy? (00:20-00:58)
  2. What did the GAIA/CLL13 study teach us about the impact of venetoclax and obinutuzumab in fit patients with CLL? (00:58-01:42)
  3. What were the objectives of the current analysis? (01:42-02:18)
  4. What were the findings in terms of progression-free survival? (02:18-03:27)
  5. What will be the impact of these findings on the treatment paradigm for CLL? (01:27-04:31)

Disclosures: Barbara Eichhorst is a consultant for: Almirall, Biogen, BMS-Celgene, Janssen, Merck, Novartis, Roche and Sandoz. She has received grant/research support from: Biogen, Research Fund Flanders, Charcot Foundation Belgium, Merck, Sanofi-Genzyme and Roche. She is on the advisory board for: Almirall, Biogen, BMS-Celgene, Janssen, Merck, Novartis, Roche and Sandoz.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.

Filmed in coverage of the 27th Congress of the European Hematology Association (EHA)

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup